Go Pro
NYSE:PRGO

Perrigo Q4 2024 Earnings Report

Perrigo logo
$14.39 +0.26 (+1.84%)
As of 10:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Perrigo EPS Results

Actual EPS
$0.93
Consensus EPS
$0.92
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Perrigo Revenue Results

Actual Revenue
$1.14 billion
Expected Revenue
$1.20 billion
Beat/Miss
Missed by -$57.66 million
YoY Revenue Growth
N/A

Perrigo Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Perrigo's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Perrigo Earnings Headlines

Perrigo (NYSE:PRGO) Stock Rating Upgraded by Wall Street Zen
China's dominance in rare earth processing sparks new defense rules
On January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adversaries. China controls more than 90% of global rare earth processing capacity, while the U.S. imports 100% of its titanium sponge. SAGA Metals has drilled more than 23,000 meters at its Radar project, with all 92 drill holes intersecting mineralization. A maiden mineral resource estimate is expected in Q4 2026, alongside ongoing drilling at the Wolverine heavy rare earth project.tc pixel
Perrigo Company plc
See More Perrigo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Perrigo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Perrigo and other key companies, straight to your email.

About Perrigo

Perrigo (NYSE:PRGO) is a global consumer self-care company that develops, manufactures and markets over-the-counter (OTC) products and other nonprescription health and wellness products. Its portfolio spans consumer health categories including pain relief, allergy and cold remedies, digestive health, skin care, oral care, vitamins and supplements, and women’s health.

The company sells products under both its own brands and retailer-owned store brands through pharmacies, supermarkets, mass merchants, e-commerce channels and other outlets. Well-known brands associated with Perrigo include ACO, Compeed, Mederma and HRA Pharma’s women’s health products. In the United States, Perrigo markets Opill, a progestin-only oral contraceptive that became the first daily birth-control pill available over the counter in the country.

Perrigo traces its origins to 1887, when it began as a small retail business in Allegan, Michigan. It has since expanded through product development and acquisitions, with operations and commercial activities serving consumers primarily in North America and Europe, as well as selected international markets. Perrigo Company plc is incorporated in Ireland and is led by President and Chief Executive Officer Patrick Lockwood-Taylor.

View Perrigo Profile